Lung CancerSCOOTNCT05368298
SCOOT: Sample Collection for DART
An observational study of Lung Cancer, run by University of Oxford at 11 sites in United Kingdom.
Trial summary
The study will use a blood sample collected from participants to: Develop new ways of finding and diagnosing lung health problems, such as lung cancer. Develop tools which make it easier to screen people with possible lung health problems, diagnose problems earlier and with fewer tests, and start the best treatment… Read more about this study
- Who is it for?
- Ages 55 to 75 years
- Conditions the study is for
- Lung Cancer
- How many people
- 872 participants
- Where
- 11 sitesUnited Kingdom
- Study dates
- 11 Aug 2022to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have been offered follow up appointments after their Lung Health Check. Patients may be invited to attend a Lung Health Check if they have ever smoked and are aged 55 - 75 years old.
Who may be able to join
- Patients with a pulmonary nodule or nodule(s) detected on a CT scan performed as part of Lung Cancer Screening from the Lung Health Check centres, that require further investigation with a PET-CT scan, and / or biopsy, and / or resection
- Willing and able to give informed consent
Who cannot join
- None -
Trial locations and contacts
11 sites in 1 country.
11 sites in 1 country
United Kingdom11 sites
Lung Health Check Centre: Royal Sussex
Brighton
Lung Health Check Centre: North Bristol
Bristol
Lung Health Check Centre: Gateshead
Gateshead
Lung Health Check Centre: Corby & Kettering
Kettering
Lung Health Check Centre: Cheshire & Merseyside
Liverpool
Lung Health Check Centre: RM Partners
London
Lung Health Check Centre: Newcastle & Gateshead
Newcastle
Lung Health Check: Oxford - Churchill Hospital, OUH
Oxford, Oxfordshire
Lung Health Check Centre: Plymouth
Plymouth
Lung Health Check Centre: Stoke
Stoke
Lung Health Check Centre: South Tyneside and Sunderland
Sunderland
About this study
Official title: Sample Collection for The Integration and Analysis of Data Using Artificial Intelligence to Improve Patient Outcomes With Thoracic Diseases
The study will use a blood sample collected from participants to:
- Develop new ways of finding and diagnosing lung health problems, such as lung cancer.
- Develop tools which make it easier to screen people with possible lung health problems, diagnose problems earlier and with fewer tests, and start the best treatment faster.
- Help improve the early diagnosis of lung cancer, as finding lung cancer early means that it can be treated more easily and successfully.
Read the detailed description
The results from this study will be linked with the data from the DART study (also collecting data through the Lung Health Check programme) to develop new ways of using computer technology (artificial intelligence) to improve lung health care. The studies use computer programs (called 'algorithms') which can be trained to analyse medical samples. Once developed, these algorithms can be used to support doctors by increasing their speed and accuracy of diagnosing issues.
- Conditions
- Lung Cancer
- Keywords
- screening, lung health check, artificial intelligence, algorithm, diagnosis, detection, blood, blood test, early detection, lung, lung cancer, lung screening, AI, biomarker
- Medical subject headings
- Lung Neoplasms, Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
To develop an algorithm that gives a greater than chance improved ability to diagnose lung cancer using the blood biomarkers with or without the AI CT algorithm compared to not using them
Measured: by 30Sep2027
Secondary outcomes (1)
To develop an algorithm that gives a greater than chance improved ability to diagnose lung cancer using the blood biomarkers with or without the AI CT and blood markers algorithm compared to not using them
Measured: by 30Sep2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2022
- Study start11 Aug 2022
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 872 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- Innovate UK, Optellum, National Institute for Health Research, United Kingdom, Cancer Research UK, GE Healthcare, Roche Diagnostics GmbH, GlaxoSmithKline, Prenostics
- Responsible party
- Sponsor
- Investigators
- Richard Lee, Principal investigator, Royal Marsden NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05368298
- Sponsor's protocol ID
- OCTO-106
- Acronym
- SCOOT
- Status last verified
- May 2026
- First submitted
- 5 May 2022
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The data sharing plans for the current study are unknown and will be made available at a later date.
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sample Collection for The Integration and Analysis of Data Using Artificial Intelligence to Improve Patient Outcomes With Thoracic Diseases
- ClinicalTrials.gov ID
- NCT05368298
- Acronym / sponsor ID
- SCOOT / OCTO-106
- Conditions
- Lung Cancer
- Keywords
- screening, lung health check, artificial intelligence, algorithm, diagnosis, detection, blood, blood test
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 872 participants (actual)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Collaborators
- Innovate UK, Optellum, National Institute for Health Research, United Kingdom, Cancer Research UK, GE Healthcare, Roche Diagnostics GmbH, GlaxoSmithKline, Prenostics
- Study start
- 11 Aug 2022 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 10 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will use a blood sample collected from participants to:
- Develop new ways of finding and diagnosing lung health problems, such as lung cancer.
- Develop tools which make it easier to screen people with possible lung health problems, diagnose problems earlier and with fewer tests, and start the best treatment faster.
- Help improve the early diagnosis of lung cancer, as finding lung cancer early means that it can be treated more easily and successfully.
Detailed description
The results from this study will be linked with the data from the DART study (also collecting data through the Lung Health Check programme) to develop new ways of using computer technology (artificial intelligence) to improve lung health care. The studies use computer programs (called 'algorithms') which can be trained to analyse medical samples. Once developed, these algorithms can be used to support doctors by increasing their speed and accuracy of diagnosing issues.
Study design
- Observational model
- Other
- Time perspective
- Other
Who may qualify
- Ages
- 55 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have been offered follow up appointments after their Lung Health Check. Patients may be invited to attend a Lung Health Check if they have ever smoked and are aged 55 - 75 years old.
Key inclusion criteria (2 listed)
- Patients with a pulmonary nodule or nodule(s) detected on a CT scan performed as part of Lung Cancer Screening from the Lung Health Check centres, that require further investigation with a PET-CT scan, and / or biopsy, and / or resection
- Willing and able to give informed consent
Key exclusion criteria (1 listed)
- None -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To develop an algorithm that gives a greater than chance improved ability to diagnose lung cancer using the blood biomarkers with or without the AI CT algorithm compared to not using them
Time frame: by 30Sep2027
1 secondary outcome
To develop an algorithm that gives a greater than chance improved ability to diagnose lung cancer using the blood biomarkers with or without the AI CT and blood markers algorithm compared to not using them
Time frame: by 30Sep2027
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- OCTO webpage containing information about the SCOOT trialLink provided by the sponsor.
- Cancer Research UK webpage containing information about the Lung Health Check programmeLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. The data sharing plans for the current study are unknown and will be made available at a later date.
Related trials for Lung Cancer
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Lee principal investigator
Royal Marsden NHS Foundation Trust
11 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by University of Oxford at 11 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To develop an algorithm that gives a greater than chance improved ability to diagnose lung cancer using the blood biomarkers with or without the AI CT algorithm compared to not using them (time frame: by 30Sep2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.